A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

December 13, 2018

Study Completion Date

August 8, 2019

Conditions

Narcolepsy

Interventions

DRUG

TS-091 5mg

Orally taken once daily for 3 weeks

DRUG

TS-091 10mg

Orally taken once daily for 3 weeks

DRUG

Placebo

Orally taken once daily for 3 weeks

Trial Locations (2)

Taisho Pharmaceutical Co., Ltd selected site, Osaka and Other Japanese City

Taisho Pharmaceutical Co., Ltd selected site, Seoul and Other Korean City

All Listed Sponsors

lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT03267303 - A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy | Biotech Hunter | Biotech Hunter